vimarsana.com
Home
Live Updates
F. Hoffmann-La Roche Ltd: Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) - a key marker for hereditary cardiovascular risk : comparemela.com
F. Hoffmann-La Roche Ltd: Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) - a key marker for hereditary cardiovascular risk
Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics Tina-quant®
Related Keywords
Kamstrup ,
Sjæand ,
Denmark ,
Langsted ,
Syddanmark ,
Japan ,
Copenhagen ,
Køavn ,
Canada ,
Beijing ,
China ,
United States ,
Switzerland ,
America ,
Canadian ,
Matt Sause ,
Sabine Borngr ,
Karsten Kleine ,
Rebekka Schnell ,
Simon Goldsborough ,
Birgit Masjost ,
Yvette Petillon ,
Jay Bradner ,
Nathalie Altermatt ,
Sileia Urech ,
Loren Kalm ,
Kirti Pandey ,
Bruno Eschli ,
European Society Of Cardiology ,
Canadian Cardiovascular Society ,
Breakthrough Devices Program ,
Amgen ,
Heart Society ,
Genentech ,
European Atherosclerosis Society ,
Roche Group ,
Drug Administration ,
National Lipid Association ,
Roche Diagnostics Tina Quant ,
Breakthrough Device Designation ,
European Society ,
Beijing Heart Society ,
Dow Jones Sustainability Indices ,
Chugai Pharmaceutical ,
Copenhagen General Population ,
Ihr Portfolio ,
comparemela.com © 2020. All Rights Reserved.